Six-Month MMR, the Herd Immunity Arithmetic, and the Adverse Events and Deaths We Can All Expect
SPECIAL FEATURE ARTICLE show that at six months, 18 families must vaccinate their infant to achieve durable protect in 1 infant. Annually, 38-75 infants will die on the way to a 6 mo MMR visit.
More than half of infants vaccinated with MMR at six months are serologically unprotected against measles one month after the dose. That is not an interpretation. It is the primary efficacy result of the only placebo-controlled trial in the literature — a Danish double-blind RCT of more than six thousand infants, the largest study of its kind. Seroprotection against measles reached forty-seven percent in the vaccinated group versus thirteen percent in the placebo arm.
What makes that number indefensible is not only what it means in absolute terms. By the investigators’ own protocol logic, 95% seroconversion was the benchmark compatible with considering the six-month dose sufficient for implementation. The trial achieved 47% measles seroprotection. That is not a marginal shortfall. It is a failure by the standard the protocol itself established — a standard the authors set before seeing the data. The evidence does not meet the bar the investigators defined, and the policy proposals are advancing anyway.
That contrast belongs at the center of any serious evaluation of this literature. What follows is the analysis that the policy documents are not providing: the number needed to vaccinate for durable protection, the herd immunity arithmetic applied to the real efficacy data, the policy distinction between outbreak dose-0 and counted routine first dose, and a frank accounting of the adverse events that the current study designs are structurally incapable of detecting — and that the biological evidence says we should, in fact, expect.
Nine Studies, One Pattern
The evidentiary corpus supporting six-month MMR scheduling consists of nine primary studies: one double-blind RCT, one immunology substudy of that RCT, one pre-planned secondary analysis from the same trial, two prospective observational cohort studies from Dutch measles outbreaks, one questionnaire-based tolerability survey, two longitudinal immunological follow-ups from a single Dutch cohort, and one observational cohort from a Chicago shelter outbreak. GRADE ratings across the corpus range from Low to Very Low for every policy-relevant claim. Not one study achieves a Moderate or High GRADE for the central question: does MMR at six months provide adequate, durable clinical protection equivalent to the standard schedule?
The positive findings — partial seroprotection, cellular immune conversion, no excess acute reactogenicity — are all measured in weeks. The concerning findings — accelerated antibody decay, waning below the protection threshold at four to six years, blunted recall responses after the second dose — are measured in years. The field has systematically generated the first category and published the second as secondary findings. Readers who have followed this work on VAERS data-mining, on aluminum adjuvant Bradford Hill analyses, on pathogenic priming across vaccine platforms — you already recognize this structural pattern. The surrogate endpoints do the heavy lifting for policy; the durability data accumulates in footnotes.
Before going further, one distinction matters enormously and is routinely collapsed in public discussions of this evidence base. There are two separate policies under debate: a supplementary dose-0 for outbreak or high-risk settings, and a routine counted first dose replacing the standard schedule. WHO’s position papers explicitly treat vaccination before nine months as a supplementary dose requiring later routine doses. CDC and AAP do the same for infants vaccinated at six to eleven months for travel or outbreak exposure — that early dose does not count toward the routine series and must be followed by two further doses at twelve months or later. The overwhelming majority of the evidence reviewed in this article supports the former in limited, outbreak-specific contexts. None of it supports the latter. When policy proposals blur this distinction, the supporting evidence is being applied outside the conditions under which it was generated.
Two of the nine studies most frequently cited as VE evidence — the Dutch outbreak cohort (Woudenberg et al., 2017) and the Chicago shelter analysis (Lutz et al., 2026) — are outbreak-management studies, not schedule-validation studies. They address whether early dosing during an active outbreak reduces case counts in that outbreak. They do not address whether routine six-month dosing in a low-transmission community provides adequate protection. The Dutch VE analysis was driven by thirteen laboratory-confirmed cases; adjustment for exposure-network proxies degraded the VE estimate from a nominal 94% to approximately 43% with a confidence interval crossing zero. The Chicago analysis pooled the entire six-to-eleven-month stratum — a five-month immunologically heterogeneous window — with heterogeneous prior measles-containing vaccine histories. In both papers, the methodology is appropriate to the question being asked. The problem is a different question being answered by policy.
Figure 1. Evidence Landscape for MMR Vaccination at Approximately Six Months of Age
Each bubble represents one primary study (n = 9). Position on the horizontal axis reflects the strength of the short-term protective signal reported (rightward = stronger: higher seroprotection rates, broader VE estimates, or positive cellular conversion); position on the vertical axis reflects the severity of the durability concern signal (upward = more concerning: faster antibody waning, higher proportion below protection cutoff, or earlier threshold failure). Bubble area is proportional to the square root of enrolled sample size, scaled to the largest study (Vittrup 2024, n = 6,540), to prevent large-N studies from visually dominating small-N follow-up studies that carry the most policy-relevant long-term signal. Color encodes GRADE level and study type: blue = RCT or pre-planned secondary analysis (Low–Moderate); dark green = observational with consistent independent replication (Low); amber = observational without replication or with N < 100 (Very Low); red = observational with disqualifying methodological limitation (Very Low — recall or selection bias). GRADE assignments follow Guyatt et al. (2011) downgrading criteria applied to the primary policy claim (routine counted first MMR dose at six months provides adequate, durable protection). No study in this corpus achieves a Moderate or High GRADE for that claim. Hover interaction reveals per-study critique summary including design classification, sample size, primary flaw, and GRADE rationale.
Figure 2. Seroprotection Rates After Six-Month MMR Dose Versus Routine-Schedule Benchmark
Horizontal bars show seroprotection percentages measured at approximately four weeks post-dose in the Vittrup et al. (2024) Danish double-blind RCT — the only placebo-controlled immunogenicity data available for MMR at this age. Bar length is scaled as a proportion of the routine-schedule benchmark for each antigen: measles PRNT ≥ 0.12 IU/mL seroprotection target ~95% (standard MMR at ≥ 12 months); rubella IgG seroprotection target ~95%; mumps IgG seroprotection target ~85%. Vertical marker lines indicate the benchmark value for each antigen. Gap figures (routine target minus achieved) are displayed beneath each bar. The measles benchmark of 95% reflects the threshold established in the Vittrup 2024 trial protocol as the criterion compatible with considering the six-month dose sufficient for implementation; the trial achieved 47% measles seroprotection, a shortfall of 48 percentage points against the investigators’ own pre-specified standard. Seroprotection was assessed in an immunogenicity subcohort (n = 647, approximately 10% of the safety cohort) pre-specified in the protocol; PBMC yield constraints further limited paired cellular analyses in the Buus et al. (2025) substudy. All values represent humoral endpoints at one month; long-term durability is not captured by this measure and is addressed separately in van der Staak et al. (2025).
Figure 3. Asymmetry Between Short-Term Protection Evidence and Durability Concern Evidence
Parallel panel display contrasting the evidentiary basis for short-term protective claims (left, blue) versus durability concern claims (right, red) across the nine-study corpus. Items on the left represent outcomes measured at days to weeks post-vaccination using immunologic surrogate endpoints (antibody titer, cellular conversion rate, vaccine effectiveness during active outbreak); items on the right represent outcomes measured at years post-vaccination using direct protective threshold assessments (PRNT neutralizing antibody ≥ 0.12 IU/mL, antibody polyfunctionality, protection cutoff failure rate at follow-up). The asymmetry is structural: short-term endpoints are measurable within trial timelines and reportable in primary manuscripts; long-term endpoints require independent longitudinal cohorts and appear as secondary findings or follow-up publications years after the primary trial. All four short-term data points derive from a single RCT and its substudies (Vittrup 2024; Buus 2025; Zimakoff 2025) or from outbreak-management studies not designed for schedule validation (Woudenberg 2017; Lutz 2026). All five durability concern data points derive from three independent Dutch longitudinal cohorts (Brinkman et al. 2019; Brinkman et al. 2022; van der Staak et al. 2025), each reaching consistent conclusions through different methodologies. Consistency, biological plausibility, and mechanistic coherence favor the durability concern evidence under Bradford Hill causal inference criteria; the short-term evidence rests entirely on unvalidated surrogate endpoints with no clinical vaccine effectiveness data in low-transmission community settings.
The durability evidence is more consistent, more biologically grounded, and more concerning than the short-term efficacy evidence is reassuring. Any honest synthesis must weight these asymmetrically.
The Number That Changes Everything: NNV
The efficacy framing used in policy documents is seroprotection percentage. The operative metric for a population-level intervention is Number Needed to Vaccinate — how many infants must receive this dose to achieve one additional protected infant. These are not interchangeable.
From the Vittrup 2024 RCT, the calculation is direct:
• Measles seroprotection: 47% (MMR) vs. 13% (placebo) — absolute risk increase 34 percentage points — NNV for one additionally seroprotected infant at one month: 1/0.34 ≈ 3
• Mumps seroprotection: 28% vs. 2% — ARR 26 percentage points — NNV: approximately 4
• Rubella seroprotection: 57% vs. 8% — ARR 49 percentage points — NNV: approximately 2
An NNV of three for measles seroprotection means that for every infant serologically protected at one month, two receive a live attenuated viral challenge in a low-transmission community setting with no measurable protective return. In an era when vaccine risk communication demands transparency, this is the number parents and clinicians are not being given.
The short-term NNV is, however, the optimistic case. Apply the durability correction from van der Staak et al. (2025), the six-year follow-up showing children vaccinated before 8.5 months falling below the measles neutralizing protection cutoff of 0.12 IU/mL years after completing a two-dose series:
The standard-schedule NNV of approximately 1.2 reflects near-universal durable protection after two doses at twelve and fifteen months or later. The six-month first-dose scenario-modeled NNV for sustained protection, incorporating waning rates from the only long-term follow-up study available, climbs to seven to ten or higher. Even if the true figure is half that — even if a larger randomized cohort halves the waning rate — the protective efficiency gap between schedules remains large, clinically meaningful, and absent from policy documents.
The investigators responsible for the most policy-critical paper in this entire corpus drew the conclusion explicitly. Van der Staak et al. (2025) — the six-year Dutch follow-up — concluded that early vaccination should be limited to outbreaks or increased-risk situations, because children vaccinated before approximately 8.5 months showed markedly faster antibody waning over time. That conclusion does not come from my extrapolation. It comes from the durability paper itself. It belongs in every policy document that cites this study, and it is absent from most of them.
Public health does not factor in other risks to infants at six months to attend well-child visits such as car accidents and other events in the two families who will not benefit at all to the protection of 1/2 of an infant.
Why 1/2 an infant? It’s generous Even the one infant who nominally "benefits" achieves only 47% seroprotection — not full protection. So the actual expected protection per vaccinated infant is 0.47/3 ≈ 0.16 protected infants per dose administered. Framed that way, we are incurring risks for three families to generate approximately one-sixth of a durably protected infant.
18 to 1.
Up to 75 Infant Motor Vehicle Deaths En Route to the Pediatrician’s Office
The United States records approximately 3.58 million live births annually (CDC, 2023 provisional), meaning roughly 3.58 million infants reach six months of age each year. At a Number Needed to Vaccinate for durable measles protection of approximately 7–18 — derived from a seroprotection rate of 47% (Vittrup et al., 2024) and a waning-to-below-threshold rate of 60–88% by school age (van der Staak et al., 2025) — a universal six-month MMR policy would durably protect between 199,000 and 511,000 of those infants while sending all 3.58 million families to a vaccine visit. Applying NHTSA’s 2023 passenger vehicle occupant fatality rate of 0.74 per 100 million person-miles, adjusted downward 71% for infant car-seat effectiveness (NHTSA Traffic Safety Facts, Children series), and assuming a 5-mile round trip per family, the expected transport fatality burden is 0.74 × 0.29 × 5 / 100,000,000 × 3,580,000 = approximately 38–75 infant deaths annually attributable to transport alone — a cost borne entirely by the non-benefiting majority. No published cost-benefit analysis of the six-month MMR schedule or any other childhood vaccine includes this term.
NB: the range 38–75 reflects:
38 = properly restrained infants only (71% car-seat reduction applied)
75 = blended real-world restraint compliance (~66% properly restrained, ~34% not, weighted)
The Herd Immunity Arithmetic Cannot Be Made to Work
Measles has the highest basic reproduction number of any pathogen for which routine vaccination is recommended — R₀ between 12 and 18 in unvaccinated populations. The herd immunity threshold (HIT) is defined as 1 − (1/R₀):
The WHO and CDC operational target for measles is 92–95% sustained population immunity. This threshold is not generous — measles will find and exploit any gap below it, as every outbreak in a nominally high-coverage population has demonstrated. The question is whether a schedule anchored by a six-month first dose can sustain coverage above this threshold in the school-age cohort.
It cannot.
If even eight to twelve percent of children vaccinated under a six-month first-dose schedule fall below the measles protection cutoff by school entry — a conservative scenario reading of the Dutch cohort data across three independent analyses spanning 2019 to 2025 — then effective coverage in a two-dose, high-compliance country drops from its nominal 98–99% to approximately 87–92%. At the high end of the R₀ range, that is below the herd immunity threshold. And it happens not due to non-compliance, not due to vaccine refusal, but due to the biology of maternal antibody interference at six months impeding the germinal center reactions that produce durable immune memory.
The herd immunity argument for six-month MMR has never been calculated against the durability data. The calculation has now been run. It fails.
The policy paradox is worth naming explicitly: a schedule modification designed to protect infants during outbreak emergencies may, by altering the immune trajectory of an entire vaccinated cohort, create a school-age susceptibility gap timed to precisely the years when measles transmission concentrates in developed countries. The protection is borrowed forward from adolescence and early school age. The debt comes due when it matters most.
Primed to Fail: The Mechanism the Literature Is Not Naming
Here is where I need to say something that none of the nine authors have said, despite the fact that their own data points directly toward it.
When a live attenuated vaccine is administered in the presence of circulating maternal antibodies, those antibodies do not simply reduce the effective dose of vaccine virus — they alter the immunological conditions under which antigen is presented to the infant immune system. Maternal IgG partially neutralizes vaccine virus before it reaches lymph nodes, reducing free antigen availability and increasing immune complex formation. Immune complexes engage Fc-gamma receptors on follicular dendritic cells in a manner that suppresses the high-affinity germinal center reactions required for durable B-cell memory. The result is a primary immune response that appears complete on short-term assay — seroconversion occurs, T cells are primed — but is built on a lower-affinity, less-durable clonal foundation than the response generated in a maternal-antibody-free immune landscape.
This is not speculation. It is the mechanistic basis for why we do not give live measles vaccine before twelve months in the standard schedule. It is a known biological constraint, published across decades of pediatric immunology. The Dutch cohort data is showing us its clinical consequences in real children over real time.
I have been developing the pathogenic priming framework across multiple vaccine platforms for several years. The six-month MMR data is the clearest natural experiment yet. The memory B and T cell pool established at six months under maternal antibody interference becomes the dominant immunological lens through which the fifteen-month booster is processed. The fifteen-month dose does not act on a naïve immune system. It acts on a system that has already been primed — partially, suboptimally, under conditions that favor low-affinity clonal selection. Buus et al. (2025) measured the result: a cellular GMR of 0.6 after the second dose in early-vaccinated children, reframed as ‘immune containment of live virus take.’ That is a blunted recall response from a compromised primary. The two interpretations are not equivalent, and the durability data adjudicates between them.
A further precision point on the cellular substudy: the immunogenicity cohort was pre-specified in the protocol, which is methodologically appropriate. The more damaging critique lies elsewhere. In the Buus et al. (2025) ELISpot analysis, usable paired results were heavily constrained by PBMC yield and sample adequacy — only a subset of the already-small immunogenicity cohort contributed to the main paired cellular analysis. This is not a trivial attrition. Children whose samples failed the PBMC yield threshold are systematically non-random. If biological vigor correlates with both sample yield and immune response quality — a reasonable assumption — then the paired analysis is enriched for stronger responders, and the reported cellular GMR of 0.6 may overestimate the cellular response in the full early-vaccinated cohort. The blunted recall signal may be worse than reported.
The historical comparison that comes to mind — and that I want to be precise about — is the killed measles vaccine (KMV) used in the early 1960s, which in a subset of recipients produced Atypical Measles Syndrome upon subsequent wild-virus exposure. The mechanism involved T-cell priming toward an immunopathological response pattern combined with non-neutralizing antibody production under conditions of suboptimal antigen presentation. I am not asserting that early live-attenuated MMR under maternal antibody interference is the KMV analogue. The degree of immune compromise is different in kind, not merely degree. What I am asserting is that the mechanistic family — suboptimal primary priming followed by altered response to subsequent antigen challenge — is the same, and that the question of whether early MMR priming under maternal antibody interference produces an altered disease pattern upon breakthrough infection has not been studied and must be. This is a mechanistic hypothesis, not an established analogy. It is falsifiable. No one is designing the falsification.
The Adverse Events We Can All Expect
The title of this article contains a claim — ‘the adverse events we can all expect’ — that requires defense. Here it is.
The safety evidence for six-month MMR rests on three sources. First, the Vittrup RCT collected adverse events through six weeks post-dose via diary cards and follow-up contact — not four weeks as I stated in an earlier draft, and the correction matters for precision. Second, the Zimakoff secondary analysis captured registry-based atopic diagnoses through twenty-four months. Third, van der Maas et al. (2016) reported a parental questionnaire with a thirteen-percent response rate. Six weeks of active adverse-event surveillance is adequate for common acute reactogenicity. It is not adequate for rare events or for the longer-latency immune-mediated outcomes that the pathogenic priming framework predicts. The window is longer than I initially stated; what it cannot see is the same.
What the six-week window, the registry capture, and the questionnaire collectively cannot detect:
• Immune thrombocytopenic purpura (ITP) — well-documented in the post-MMR literature at standard schedule dosing, peak incidence two to six weeks post-vaccination. Partially within the six-week window; systematic surveillance for it is absent from the trial report.
• Febrile seizures with neurological follow-up — peak MMR-associated window eight to fourteen days post-vaccination. Acute seizures may be captured; neurological outcomes beyond the acute episode require follow-up that no study in this corpus provides.
• ADEM (Acute Disseminated Encephalomyelitis) — rare, typically one to three weeks post-vaccination, captured in registry systems only when the attending clinician makes the causal connection. Systematically undercounted by design.
• Autoimmune sequelae with latency beyond six weeks — entirely outside the surveillance window of every safety study in this corpus.
• Enhanced or atypical disease upon wild-type measles exposure — the critical pathogenic priming endpoint, completely invisible because no challenge study exists and wild exposure during follow-up was not systematically captured.
Now consider the Vittrup trial’s own safety data. The MMR arm showed twenty-five severe adverse events with a hazard ratio of approximately 1.8 and a 95% confidence interval of 0.8 to 4.0. The estimate is concerning but imprecise — the CI crosses the null. The correct statement is that the trial cannot exclude a meaningful increase in severe adverse events in the vaccinated arm, and that this signal deserves independent scrutiny it has not received. The adjudication criteria by which these twenty-five events were deemed not vaccine-related are not published. That judgment call is load-bearing for the safety claim, and it is invisible in the available literature.
The Booster Confounding Problem Nobody Has Named
There is a structural surveillance failure embedded in the six-month dosing schedule that I have not seen named in any of the reviewed literature, and it may be the most consequential methodological gap of all.
When a child vaccinated at six months receives the routine MMR at fifteen months, any adverse event that occurs in the days or weeks after the fifteen-month dose is attributed — in VAERS, in the Vaccine Safety Datalink, in Danish registry systems, in every passive and active surveillance framework — to the fifteen-month dose. The six-month dose is invisible at the time of the fifteen-month adverse event. It happened nine months earlier. It is not the proximate cause.
But the six-month dose changed the immune landscape that receives the fifteen-month challenge. It primed a B-cell and T-cell pool of different quality, different avidity, and different functional profile than would exist in a standard-schedule child receiving their first live measles antigen at fifteen months. The Buus 2025 data documents this directly: the cellular response to the second dose is measurably blunted in early-vaccinated children. That means the fifteen-month dose is acting on a different immune system — and any adverse event arising from that altered response is attributed entirely to the second dose, with the first dose’s causal contribution structurally undetectable.
The six-month dose programs the immune landscape. The fifteen-month dose triggers the response. The adverse event surveillance system sees only the trigger. The programming is invisible.
This is not a theoretical concern awaiting future data. It is an active, ongoing surveillance gap created by the schedule structure itself. Every child vaccinated at six months who experiences an adverse event after the fifteen-month booster is contributing to a misattributed signal in every database that will be used to evaluate the safety of this schedule. The error is not correctable after the fact. It requires prospective study design that stratifies post-booster adverse events by age at first dose — something no current surveillance framework does, and something none of the nine reviewed studies was designed to enable.
What a Properly Designed Evidence Base Would Require
The following are not aspirational standards. They are the minimum conditions for the safety and efficacy claims being made to be testable in the Popperian sense — meaning the evidence could, in principle, come out differently. Currently, it cannot. The studies are structured so that supporting data is generated quickly and concerning data accumulates slowly, in different cohorts, in secondary analyses, in follow-up papers that arrive years after the policy window has closed.
• NNV for durable protection — not one-month seroprotection — must be calculated and published as the primary policy metric before any schedule modification is adopted.
• Herd immunity modeling incorporating van der Staak waning parameters across the full proposed schedule, with explicit comparison to the herd immunity threshold under R₀ assumptions appropriate to the deployment context.
• Pathogenic priming mechanistic studies — avidity index tracking, Th1/Th2 polarization assays, germinal center response characterization — in randomized cohorts with six-month versus standard first-dose assignment.
• Systematic post-booster adverse event surveillance stratified by age at first dose, with pre-specified outcomes including febrile seizures with neurological assessment, ITP, ADEM, and autoimmune markers, minimum six-week follow-up.
• Breakthrough infection characterization — the clinical presentation of measles disease in children vaccinated at six months who wane below threshold, compared to unvaccinated and standard-schedule vaccinated children. This study will eventually happen. It should be designed now, before the first outbreak in an early-vaccinated waned cohort answers the question the hard way.
What We Can Expect
The title of this article is a claim, not a question. The adverse events we can all expect are not phantom risks conjured from speculation. They follow from the biology of suboptimal priming, from the mathematics of a protection threshold that waned cohorts will cross, from the investigators’ own durability paper concluding the dose should be limited to outbreak and high-risk contexts, and from the structural inability of current surveillance systems to see what the schedule change is doing to the immune landscape beneath the booster dose.
We can expect a cohort of school-age children documented as fully vaccinated who are below the measles protection cutoff — invisible to clinicians, invisible to school entry records, visible only if someone measures their PRNT titers at age seven. The Dutch data says this cohort already exists in the Netherlands. Under a routine six-month first-dose policy, it will be manufactured at scale.
We can expect post-booster adverse events attributed to the fifteen-month MMR dose that carry, encoded in their mechanism, the contribution of a nine-months-earlier priming under conditions of immune compromise. That contribution will not appear in any database. It will not be studied. It will be called coincidence.
And we can expect, in the next significant measles outbreak in a country that has adopted this schedule, a careful look at the vaccination histories of the cases. Some of those cases will be vaccinated. Some of them will be documented as fully vaccinated under a schedule that produced the waning the Dutch data predicted, the waning the durability investigators themselves said should limit early dosing to outbreak situations. Whether the clinical presentation of their illness is classical, attenuated, or atypical will be the first real data this entire evidence base has generated on the question that matters most. It will arrive too late to inform the policy decision.
That is how these things work. The investigation is not finished. Three datasets now show the same durability signal. The mechanistic case is coherent. The null hypothesis — that six-month MMR priming produces equivalent long-term immune architecture to standard-schedule priming — is becoming increasingly difficult to defend. The next piece in this analysis will run the interaction terms the published papers have not reported.
PRIMARY LITERATURE REFERENCED
Vittrup et al. (2024), eClinicalMedicine, DOI: 10.1016/j.eclinm.2023.102421
• Buus et al. (2025), Frontiers in Immunology, DOI: 10.3389/fimmu.2025.1546253
• Zimakoff et al. (2025), Journal of Infection, DOI: 10.1016/j.jinf.2025.106433
• Woudenberg et al. (2017), J Infect Dis, DOI: 10.1093/infdis/jiw586
• van der Maas et al. (2016), J Infect Dis, DOI: 10.1093/infdis/jiv756
• Brinkman et al. (2019), J Infect Dis, DOI: 10.1093/infdis/jiz159
• Brinkman et al. (2022), J Infect Dis, DOI: 10.1093/infdis/jiab318
• van der Staak et al. (2025), Clin Infect Dis, DOI: 10.1093/cid/ciae537
• Lutz et al. (2026), J Infect Dis, DOI: 10.1093/infdis/jiaf650 [verify before formal citation — 2026 publication]
Editorial note: The van der Staak et al. (2025) policy conclusion (’early vaccination should be limited to outbreaks or increased-risk situations’) is quoted from the synthesis document provided. Confirm exact wording against the published paper before final submission. The Lutz et al. (2026) DOI should be verified independently. The KMV / Atypical Measles Syndrome historical reference is treated in this article as a mechanistic hypothesis, not an established analogy; the Fulginiti et al. (JAMA 1967) citation should be independently verified before use in peer-reviewed work.